MKI67 and breast carcinoma: Finally, our analysis of the molecular group using the competitive risk model showed that only belonging to the triple-negative group means a worse survival rate than the reference group (Luminal with unknown Ki67), i.e., the risk of dying from breast cancer in this group is almost double that of the other groups.